Prostatype Genomics
IntervjuVideo
| Published December 14, 2023

BioStock Investor Pitch: Prostate Genomics

Prostatype Genomics has begun commercialization of its prognostic genetic test Prostatype for confirmed prostate cancer. Going forward, the company will aim for a launch in the US, as well as sales in selected markets in Europe and Asia. The company is now raising capital to finance the commercialization and activities in the US. The company's CEO Fredrik Persson visited the BioStock studio to tell more about the plans going forward, and how he views the risk profile of the company.

Se Prostatype Genomics vd Fredrik Persson present the company here.

More information about Prostatype's new issue can be found on the company's website. issue website.

This material has been prepared for marketing purposes and is not, and should not be considered to constitute, a prospectus under applicable laws and regulations. The full terms of the rights issue and more information about the company have been set out in a prospectus on the company's website prostatypegenomics.com.